The American pharmaceutical and biotechology giant Baxter is investing EUR 138 million in Krems, Austria under its new name of Baxalta. The production facility in Krems will be expanded and modernized, creating 100 new jobs.
The American pharmaceutical group Baxter is divided as of now into new separate publicly listed companies, one for its medical products and the other for its bioscience operations. The biotech division will be called Baxalta effective immediately. The Austrian plants in Krems and Orth/Donau both fully belong to the new biotech company Baxalta.
The project which was announced calls for a blood clotting drug to be produced in Krems starting in 2018. “Over the past years we have had good experience with our production plant in Krems. Not only do we find very well trained employees here, but above all the possibility to partner with IMC University of Applied Sciences Krems and other specific facilities provides many advantages. For this reason, last year we reached an agreement to cooperate with IMC on research projects”, says Michael Heinrich of Baxalta, justifying the decision.